Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770437 | 0.93 | GRM5 (0.49) | GRM5HRH3GRIN2B | |
| SCHEMBL3763107 | 0.92 | HRH3 (0.43) | GRM5HRH3CYP11B1CYP11B2NPSR1 | |
| SCHEMBL3774800 | 0.92 | SMO (0.41) | GRM5HRH3CYP11B1CYP11B2SMO | |
| SCHEMBL3779465 | 0.90 | MEN1 (0.43) | GRM5HRH3CYP11B1CYP11B2NPSR1 | |
| SCHEMBL3765872 | 0.88 | MEN1 (0.43) | GRM5HRH3CYP11B1CYP11B2NPSR1 | |
| SCHEMBL3771792 | 0.87 | SMO (0.42) | GRM5HRH3ACACBACACACYP11B1 | |
| SCHEMBL3767924 | 0.87 | HRH3 (0.46) | HRH3CYP11B1CYP11B2SMONPSR1 | |
| SCHEMBL3769085 | 0.87 | HRH3 (0.50) | HRH3CYP11B1CYP11B2HTT | |
| SCHEMBL3780493 | 0.87 | GRM5 (0.41) | GRM5HRH3ACACBACACACYP11B1 | |
| SCHEMBL3771180 | 0.86 | HRH3 (0.42) | GRM5HRH3SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | GRM5 647/4885HRH3 2/4885ACACB 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.